{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"17.2","value":"8.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"B1: 10mg/daily LBH589 on days 1, 3 and 5 of weeks 1-4 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1.\n\nB2: 20mg/daily LBH589 on days 1, 3 and 5 of weeks 1-4 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1.","id":"OG000","title":"Melphalan and Panobinostat Schedule B"}],"paramType":"MEDIAN","populationDescription":"Only three patients had responses.","reportingStatus":"POSTED","timeFrame":"First evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}